The U.S. Food and Drug Administration approved the abbreviated new drug application July 26. This new AB-rated product is the first approved generic for the Reference Listed Drug (RLD) Oxycodone HCl 5 mg capsules manufactured by Lehigh Valley Technologies Inc.
Pain Therapeutics Inc. a biopharmaceutical company, today announced the issuance of four patents by the U.S. Patent and Trademark Office covering REMOXY (oxycodone) Extended-Release Capsules CII. These patents are the result of joint inventive work by scientists from both Pain Therapeutics and Durect Corporation. The four issued patents are licensed exclusively to Pain Therapeutics in the United States and international markets with regards to four opioid drugs.